Abstract 2929
Background
The human microbiome has been suggested to be involved in the regulation of response to anticancer strategies, however, information about how commensal microbes in a cancer patient change during radiotherapy is limited and the relationship between the microbiome and response to radiotherapy is poorly studied.
Methods
Sixty-two patients with nasopharyngeal carcinoma scheduled for radiotherapy-based treatment were prospectively enrolled. Nasopharyngeal swab samples were collected longitudinally during radiotherapy, and their microbial composition was assessed using 16S rRNA sequencing. All patients were followed up to 24 months after completion of radiotherapy.
Results
The beta-diversity of nasopharyngeal microbial communities (np-microbiome) showed changes throughout radiotherapy-based treatment. The magnitude of changes in the np-microbiome was stably and statistically significantly different between early and late responders (P = 0.02), with greater changes in early responders. This was confirmed in a temporal network analysis, where the networks varied widely in early responders, but were significantly more constrained in late responders (P = 0.009). Operational taxonomic units (OTUs) mapped to Corynebacterrium, Staphylococcus and Anaerococcus showed increasing loss with treatment, while all other abundant OTUs were stable over treatment. Twenty-seven abundant OTUs differed statistically, significantly (P < 0.05) by patients’ response throughout the treatment period.
Conclusions
The nasopharyngeal microbiome in NPC patients changes during radiotherapy-based treatment. These changes are statistically, significantly associated with patients’ response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society; Swedish Research Council; National Natural Science Foundation of China; China Scholarship Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract
3186 - The landscape of immuno-oncology clinical trials in China
Presenter: Dawei Wu
Session: Poster Display session 3
Resources:
Abstract
3468 - Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.
Presenter: Samia Hajem
Session: Poster Display session 3
Resources:
Abstract
3836 - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
Presenter: Wim Meer
Session: Poster Display session 3
Resources:
Abstract
1343 - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
Presenter: Thura Win Htut
Session: Poster Display session 3
Resources:
Abstract
5783 - Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials
Presenter: Guru Sonpavde
Session: Poster Display session 3
Resources:
Abstract
5422 - EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
Presenter: Marie Kostine
Session: Poster Display session 3
Resources:
Abstract
1202 - Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)
Presenter: Shinichi Sasaki
Session: Poster Display session 3
Resources:
Abstract
2749 - Use of Checkpoint Inhibitors (CPI) in Allogeneic Stem Cell Transplant Recipients: An Institutional Experience and A Systemic Review of the Literature
Presenter: Chantal Saberian
Session: Poster Display session 3
Resources:
Abstract
3256 - Deep Learning Radiomics distinguishes intrapulmonary Disease from Metastases in Immunotherapy-treated Melanoma Patients
Presenter: Thi Dan Linh Nguyen-Kim
Session: Poster Display session 3
Resources:
Abstract